EFPIA laments 'unfortunate' WHO decision on Lucentis
This article was originally published in SRA
The World Health Organization's "unprecedented" decision not to put Novartis's Lucentis on its essential medicines list (EML) for wet AMD, while retaining an unlicensed drug (Roche's Avastin) on the list, sends out a "very unfortunate signal" to industry and regulators, says Richard Bergström, director general of the European industry federation EFPIA.
You may also be interested in...
Another Knockback For Roche And Novartis As CJEU Rules On Italian Competition Case
In the latest development in the long-running case pitting Novartis and Roche against the Italian competition authority over a fine imposed in 2014, the Court of Justice of the EU has confirmed that the firms’ arrangement over Avastin and Lucentis could constitute a serious restriction on competition if it involved the dissemination of misleading information. The case now goes back to the Italian court.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.
EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’
Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.